Email Us
Call Us
AUSTIN, Texas – March 26, 2026 – Altogen Labs today highlighted its broad patient-derived xenograft (PDX) capabilities for preclinical oncology research, supporting studies across common and rare cancer indications. In addition to its internally established and validated PDX models, Altogen Labs works with commercial biobanks, tumor repositories, and PDX providers to procure patient-derived tumor material and established PDX models from commercially available sources worldwide. This sourcing capability allows preclinical studies to extend well beyond a fixed internal model collection. Altogen Labs can support PDX programs involving major oncology indications as well as highly specialized tumor subtypes selected according to histology, molecular characteristics, treatment history, mutation status, biomarker expression, or other project-specific requirements.
PDX studies commonly include models of breast, lung, colorectal, pancreatic, prostate, ovarian, liver, gastric, esophageal, renal, bladder, cervical, endometrial, head and neck, thyroid, brain, melanoma, sarcoma, and hematologic malignancies. Additional indications include less common models of cholangiocarcinoma, gallbladder cancer, gastrointestinal stromal tumor, mesothelioma, thymic tumors, adrenal cortical carcinoma, neuroendocrine tumors, Merkel cell carcinoma, uveal melanoma, testicular cancer, germ cell tumors, and other rare malignancies. Altogen Labs support programs requiring rare cancers, such as adenoid cystic carcinoma, salivary gland cancers, chordoma, chondrosarcoma, osteosarcoma, Ewing sarcoma, synovial sarcoma, leiomyosarcoma, liposarcoma, malignant peripheral nerve sheath tumor, rhabdomyosarcoma, desmoplastic small round cell tumor, clear cell sarcoma, epithelioid sarcoma, angiosarcoma, hemangioendothelioma, solitary fibrous tumor, pheochromocytoma, paraganglioma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, Wilms tumor, hepatoblastoma, retinoblastoma, neuroblastoma, atypical teratoid/rhabdoid tumor, medulloblastoma, diffuse midline glioma, and other uncommon pediatric and adult malignancies.
For hematologic oncology programs, patient-derived models may also be sourced for selected leukemias, lymphomas, plasma cell malignancies, and related diseases, including acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and rarer hematologic malignancies when suitable material is commercially accessible.
Patient-derived xenograft models provide an important translational platform because tumor tissue is propagated directly from patient-derived material rather than established long-term cell lines. PDX tumors can retain key histopathological, genomic, and phenotypic features of the originating malignancy, including clinically relevant intratumoral heterogeneity and molecular alterations. These characteristics make PDX models particularly useful for evaluating therapeutic response, resistance mechanisms, biomarker-defined patient populations, combination therapies, and treatment strategies directed toward specific molecular subtypes. Altogen Labs can select PDX models according to project-specific criteria such as tumor indication, histological subtype, driver mutations, gene amplification, receptor expression, therapeutic target expression, prior treatment exposure, resistance phenotype, or other molecular characteristics. When a required model is not maintained internally, the company can work with commercial PDX repositories, biobanks, and established suppliers to identify and procure an appropriate model from any commercially available source. PDX studies can evaluate small molecules, monoclonal antibodies, antibody-drug conjugates, bispecific and multispecific antibodies, targeted therapies, nucleic acid therapeutics, immunotherapies, cell-based therapeutics, combination regimens, and other investigational agents. Study endpoints may include tumor growth inhibition, tumor regression, treatment response, survival, pharmacokinetics and pharmacodynamics, tissue and plasma collection, histopathology, immunohistochemistry, molecular analysis, and other study-specific endpoints.
Altogen Labs also supports complementary patient-derived research platforms, including patient-derived cell cultures and patient-derived organoids, allowing investigators to integrate in vitro and in vivo approaches within the same preclinical development program. These platforms can be used for compound screening, mechanistic evaluation, biomarker analysis, candidate prioritization, and subsequent confirmation of therapeutic activity in vivo. In addition to PDX models, Altogen Labs has extensive experience developing and conducting studies using cell line-derived xenograft (CDX) models, orthotopic xenografts, metastatic models, syngeneic and allograft tumor models, humanized models, patient-derived cells, and patient-derived organoids. The company has conducted preclinical oncology research continuously since 2009 and supports programs ranging from early proof-of-concept studies through advanced efficacy, pharmacology, toxicology, PK/PD, and IND-supporting research.
About Altogen Labs
Altogen Labs is a preclinical CRO supporting drug development programs across oncology, pharmacology, toxicology, and translational research. The company has extensive experience with xenograft tumor models for preclinical efficacy studies and in vivo toxicology for safety evaluation, with a strong emphasis on high-quality, reproducible study execution and full client ownership of project-specific intellectual property. Altogen Labs works with pharmaceutical, biotechnology, and academic organizations worldwide to evaluate therapeutic candidates in validated in vivo models and generate data for efficacy, safety, PK/PD, pathology, and IND-supporting studies. The company provides integrated preclinical services from early-stage evaluation through advanced development.
Contact
Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com